Skip to content

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

Markets

  • What will the FDA's decision be on Saroglitazar by Zydus Therapeutics in 2026?

    • Yes76%
    • No24%

    Volume $1.3K · Liquidity $724.3

Resolution rules

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

How to read these odds

Each price runs from $0 to $1 and can be read as the probability the market assigns to an outcome: $0.62 means roughly 62%. Prices move with every trade, so they are a crowd estimate, not a guarantee. Before trading, check the resolution rules above, the volume and the liquidity, and only risk money you can afford to lose.

Probability calculators · Glossary · Free courses